The 8th Annual Biomarkers Congress covers the key challenges and critical opportunities in go/no go decision making in early development and the integration of biomarkers into clinical development. Delegates will hear from the prominent decision makers in Rx/Dx co-development and personalised healthcare strategy for the oncology, respiratory and inflammation areas. Our expert speaker panel will also discuss the latest innovations in genomic and epigenetic biomarker discovery, along with the regulatory strategies needed to utilise advancing sequencing technologies within the scope of existing US and EU compliance frameworks.